IMBRUVICA 140 mg hard capsules clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
This study is looking at a new combination treatment for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It aims to see how well these medicines keep the cancer from growing and how safe they are.
For: chronic lymphocytic leukemiaSweden · Netherlands · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma
This study looks at new treatments for a type of blood cancer called mantle cell lymphoma that has come back or hasn't responded to earlier treatments. We're comparing a drug named Ibrutinib with standard treatments like Lenalidomide or Bortezomib, all given with Rituximab, to see which works best.
For: Relapsed/Refractory Mantle Cell LymphomaCzechia · Spain · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
This study looks at a new cell therapy called Tecartus for adults with a type of blood cancer called Richter Transformation that has come back or not responded to previous treatments. It aims to see how well it works and if it's safe.
For: Relapsed/refractory Richter Transformation (RT)France · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
This study is testing a new cell therapy called Tecartus for adults in the UK with a rare blood cancer called Waldenstrom Macroglobulinemia. It's for people whose cancer has come back or hasn't responded to previous treatments. We want to see how well it works and if it's safe.
For: Relapsed/Refractory Waldenstrom Macroglobulinemia (WM)Netherlands · Spain · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
This study is looking at a new treatment called KTE-X19 for a type of cancer called Mantle Cell Lymphoma. It's for people whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well the new treatment shrinks the cancer.
For: Relapsed/Refractory Mantle Cell LymphomaFrance · Spain · Germany